23andMe Investor Day Presentation Deck

Polygenic Scores May Predict Safety and Efficacy 23andMe is incorporating clinical genotyping into our clinical trials • Use of polygenic scores could enable more efficient clinical development and improve the probability of success • Developing drugs in genetically-defined patient populations may differentiate products based on better outcomes and improved benefit-risk profiles Providing the right drugs to the right patients Copyright © 2022 23andMe, Inc. 23andMe 53

View entire presentation